Apnimed has joined the IPO queue on the Nasdaq, hoping to raise additional funding for its late-stage oral therapy for ...

The diphenhydramine dementia risk is backed by decades of research. Learn how this common OTC sleep ingredient affects the ...

Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking the first ...

Apnimed Inc. filed for a US initial public offering, as its oral drug to treat obstructive sleep apnea moves closer to being commercialized.

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe ...

TORONTO — Health Canada has approved weight-loss drug Zepbound for treating obstructive sleep apnea in adults with obesity.

Weight-loss drugs like Ozempic and Zepbound might help protect people from health risks related to sleep apnea, a new study says. Type 2 diabetes patients taking GLP-1 drugs were overall less likely ...

The US Food and Drug Administration (FDA) has again issued a warning about a sleep drug, this time requiring a labeling change for the popular sleep drug Lunesta after data indicated that some ...

Middle-aged adults and seniors would age more gracefully -- and save a few bucks -- if they lay off prescription sleep medications, a new study says. Avoiding sleep drugs would reduce older Americans' ...